

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
TEKMIRA PHARMACEUTICALS CORPORATION		12/21/2011	CORPORATION: CANADA
RECEIVING PARTY DATA			
Name:	SILICON VALLEY BANK		
Street Address:	3003 TASMAN DRIVE		
City:	SANTA CLARA		
State/Country:	CALIFORNIA		
Postal Code:	95054		
Entity Type:	CORPORATION: CALIFORNIA		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	3832265	TEKMIRA	
CORRESPONDENCE DATA			
Fax Number:	(858)638-5016		
Phone:	8586771416		
Email:	lisa.ortiz@dlapiper.com		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>			
Correspondent Name:	DLA PIPER LLP (US)		
Address Line 1:	ATTN: LISA ORTIZ		
Address Line 2:	4365 EXECUTIVE DRIVE, SUITE 1100		
Address Line 4:	SAN DIEGO, CALIFORNIA 92121		
ATTORNEY DOCKET NUMBER:	354271-000367		
NAME OF SUBMITTER:	Troy Zander		
Signature:	/s/ Troy Zander		

CH \$40.00 3832265

Date:

12/29/2011

Total Attachments: 6

source=Tekmira - IPSA#page1.tif

source=Tekmira - IPSA#page2.tif

source=Tekmira - IPSA#page3.tif

source=Tekmira - IPSA#page4.tif

source=Tekmira - IPSA#page5.tif

source=Tekmira - IPSA#page6.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of the Effective Date by and between SILICON VALLEY BANK ("Bank") and TEKIRA PHARMACEUTICALS CORPORATION ("Grantor").

RECITALS

A. Bank has agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the "Loans") in the amounts and manner set forth in that certain Loan and Security Agreement by and between Bank, PROTIVA BIOTHERAPEUTICS, INC. and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from time to time, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement). Bank is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Bank a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Bank a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Bank a security interest in all of Grantor's right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents, Trademarks and Mask Works listed on Schedules A, B, C, and D hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof but excluding any proceeds of the Intellectual Property Collateral due to the University of British Columbia, Elan International Services, Ltd., the University of Texas System (on behalf of the University of Texas M.D. Anderson Cancer Center), the British Columbia Cancer Agency, and Talon Pharmaceuticals, Inc. pursuant to the rights of such third parties existing as of the date of this Agreement.

This security interest is granted in conjunction with the security interest granted to Bank under the Loan Agreement. The rights and remedies of Bank with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Bank as a matter of law or equity. Each right, power and remedy of Bank provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Bank of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Bank, of any or all other rights, powers or remedies.

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

Address of Grantor:

100-8900 Glenlyon Parkway
Burnaby, British Columbia
Canada V5J 5J8

Attn: _____


Address of Bank:

3003 Tasman Drive
Santa Clara, CA 95054-1191

Attn: _____

GRANTOR:

TEKMIRA PHARMACEUTICALS CORPORATION

By: 
Title: President & CEO

BANK:

SILICON VALLEY BANK


By: 
Title: DEAL TEAM LEADER

EXHIBIT A

Copyrights

Description

Registration
Number

Registration Date

None.

EXHIBIT B

Patents

<u>Description</u>	<u>Patent/App. No.</u>	<u>File Date</u>
1. Method for use of oligonucleotide therapeutics	10012010	10/29/01
2. Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents	10143545	05/09/02
3. Mucoscal vaccine and methods for using the same	10290545	11/07/02
4. Cancer vaccines and methods of using the same	10437258	05/12/03
5. Pathogen vaccines and methods for using the same	10437263	05/12/03
6. Methylated immunostimulatory oligonucleotides and methods of using the same	10437275	05/12/03
7. Liposomal antineoplastic drugs and uses thereof	10788649	02/27/04
8. Methods for encapsulating plasmids in lipid bilayers	10956425	10/01/04
9. Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity	10963999	10/12/04
10. Liposomal camptothecins and uses thereof	11294826	12/06/05
11. Liposomal antineoplastic drugs and uses thereof	11429911	05/08/06
12. Compositions and methods for stabilizing liposomal drug formulations	11667138	10/27/08
13. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use of gene transfer	11728134	03/23/07
14. Compositions and methods for treating lymphoma	12069488	02/11/08
15. Compositions and methods for the delivery of nucleic acids	12811195	02/07/11
16. Amino lipids and methods for the delivery of nucleic acids	13123307	07/01/11
17. Stable microemulsions for hydrophobic compound delivery	5478860	12/26/95
18. Sphingosomes for enhanced drug delivery	5543152	08/06/96
19. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer	5705385	01/06/98
20. Sphingosomes for enhanced drug delivery	5741516	04/21/98
21. Compositions for the introduction of polyanionic materials into cells	5753613	05/19/98
22. Novel compositions for the introduction of polyanionic materials into cells	5785992	07/28/98
23. Sphingosomes for enhanced drug delivery	5814335	09/29/98
24. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer	5976567	11/02/99
25. Methods for encapsulating plasmids in lipid bilayers	5981501	11/09/99
26. Detection of endotoxin levels in liposomes, lipid bilayers and lipid complexes	6015716	01/18/00
27. Preparation of lip-nucleic acid particles using a solvent extraction and direct hydration method	6110745	08/29/00
28. Polyamide oligomers	6320017	11/20/01
29. Methods for encapsulating plasmids in lipid bilayers	6534484	03/18/03
30. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer	6586410	07/01/03
31. Polyamide oligomers	6586559	07/01/03
32. Methods for encapsulating nucleic acids in lipid bilayers	6734171	05/11/04
33. Methods for encapsulating plasmids in lipid bilayers	6815432	11/09/04
34. Method of preventing aggregation of a lipid: nucleic acid complex	6858224	02/22/05
35. Polyanionic polymers which enhance fusogenicity	6986902	01/17/06
36. Liposomal camptothecins and uses thereof	7060828	06/13/06

37. Liposomal antineoplastic drugs and uses thereof	7244448	07/17/07
38. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer	7422902	09/09/08
39. Liposomal antineoplastic drugs and uses thereof	7452550	11/18/08
40. Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof	7811602	10/12/10
41. Liposomal camptothecins and uses thereof	12963888	12/09/10
42. Methods for encapsulating plasmids in lipid bilayers	12404837	03/16/09

EXHIBIT C

Trademarks

<u>Description</u>	<u>Serial/Registration No.</u>	<u>File Date</u>
TEKMIRA	3832265	08/10/10